Androgen receptors beyond prostate cancer: an old marker as a new target

Javier Munoz; Jennifer J. Wheler; Razelle Kurzrock

doi:10.18632/oncotarget.2831

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Androgen receptors beyond prostate cancer: an old marker as a new target

Javier Munoz _, Jennifer J. Wheler and Razelle Kurzrock

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:592-603. https://doi.org/10.18632/oncotarget.2831

Metrics: PDF 2402 views | HTML 3847 views | ?

Abstract

Javier Munoz1,*, Jennifer J. Wheler2,* and Razelle Kurzrock3

1 Hematology-Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona

2 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas

3 Center for Personalized Cancer Therapy, Division and Hematology and Oncology, Moores Cancer Center, The University of California San Diego, La Jolla, California

* These authors share first authorship

Correspondence:

Jennifer J. Wheler, email:

Keywords: androgen receptor, therapy, molecular abnormalities, phase I clinical trials

Received: October 16, 2014 Accepted: November 14, 2014 Published: November 15, 2014

Abstract

Androgen receptors (ARs) play a critical role in the development of prostate cancer. Targeting ARs results in important salutary effects in this malignancy. Despite mounting evidence that ARs also participate in the pathogenesis and/or progression of diverse tumors, exploring the impact of hormonal manipulation of these receptors has not been widely pursued beyond prostate cancer. This review describes patterns of AR expression in a spectrum of cancers, and the potential to exploit this knowledge in the clinical therapeutic setting.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2831

Publication Alerts

Reviews:

Androgen receptors beyond prostate cancer: an old marker as a new target

Abstract